RecruitingPhase 2NCT06613698

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

A Dose-Finding, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of GSK4532990 for Steatohepatitis in Adults With Alcohol-related Liver Disease (ALD)

Sponsor

GlaxoSmithKline

Enrollment

393 participants

Start Date

Sep 27, 2024

Study Type

INTERVENTIONAL

Conditions

Liver Diseases, Alcoholic

Summary

The goal of this study is to assess the safety and efficacy of GSK4532990 in participants with alcohol-related liver disease.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This Phase 2 study is testing a new drug called GSK4532990 in adults with alcohol-related liver disease to see whether it can safely improve liver health. The study is comparing GSK4532990 against placebo in adults aged 18 to 70 who have advanced chronic liver disease linked to alcohol use and meet specific liver function criteria. People with organ failure, active cancer, a history of organ transplant, recent cardiovascular events, or a BMI above 35 are not eligible. Participation involves taking the study medication, attending regular clinic visits, and having blood tests and liver function assessments throughout the trial. This summary was prepared to help patients understand the study in plain language.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGSK4532990

GSK4532990 will be administered

DRUGPlacebo

Placebo will be administered

Locations(131)

GSK Investigational Site

Chandler, Arizona, United States

GSK Investigational Site

Phoenix, Arizona, United States

GSK Investigational Site

Tucson, Arizona, United States

GSK Investigational Site

Davis, California, United States

GSK Investigational Site

Los Angeles, California, United States

GSK Investigational Site

Los Angeles, California, United States

GSK Investigational Site

Brandon, Florida, United States

GSK Investigational Site

Miami Lakes, Florida, United States

GSK Investigational Site

Atlanta, Georgia, United States

GSK Investigational Site

Indianapolis, Indiana, United States

GSK Investigational Site

Topeka, Kansas, United States

GSK Investigational Site

Marrero, Louisiana, United States

GSK Investigational Site

Detroit, Michigan, United States

GSK Investigational Site

Las Vegas, Nevada, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

Chapel Hill, North Carolina, United States

GSK Investigational Site

Cleveland, Ohio, United States

GSK Investigational Site

Philadelphia, Pennsylvania, United States

GSK Investigational Site

Arlington, Texas, United States

GSK Investigational Site

Austin, Texas, United States

GSK Investigational Site

Dallas, Texas, United States

GSK Investigational Site

Dallas, Texas, United States

GSK Investigational Site

Georgetown, Texas, United States

GSK Investigational Site

McAllen, Texas, United States

GSK Investigational Site

San Antonio, Texas, United States

GSK Investigational Site

Richmond, Virginia, United States

GSK Investigational Site

Richmond, Virginia, United States

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Buenos Aires, Argentina

GSK Investigational Site

Ciudad AutOnoma de Buenos Aire, Argentina

GSK Investigational Site

Ciudad Autonoma de Buenos Aire, Argentina

GSK Investigational Site

Rosario, Argentina

GSK Investigational Site

San Miguel de Tucumán, Argentina

GSK Investigational Site

Adelaide, South Australia, Australia

GSK Investigational Site

Melbourne, Victoria, Australia

GSK Investigational Site

Parkville Melbourne, Victoria, Australia

GSK Investigational Site

Murdoch, Western Australia, Australia

GSK Investigational Site

Perth, Western Australia, Australia

GSK Investigational Site

Calgary, Alberta, Canada

GSK Investigational Site

New Westminster, British Columbia, Canada

GSK Investigational Site

Vancouver, British Columbia, Canada

GSK Investigational Site

London, Ontario, Canada

GSK Investigational Site

Toronto, Ontario, Canada

GSK Investigational Site

Toronto, Ontario, Canada

GSK Investigational Site

Montreal, Quebec, Canada

GSK Investigational Site

Terrebonne, Quebec, Canada

GSK Investigational Site

Esbjerg, Denmark

GSK Investigational Site

Hvidovre, Denmark

GSK Investigational Site

Odense C, Denmark

GSK Investigational Site

Angers, France

GSK Investigational Site

Bobigny, France

GSK Investigational Site

Créteil, France

GSK Investigational Site

Lille, France

GSK Investigational Site

Montpellier, France

GSK Investigational Site

Rouen, France

GSK Investigational Site

Bochum, North Rhine-Westphalia, Germany

GSK Investigational Site

Berlin, Germany

GSK Investigational Site

Berlin, Germany

GSK Investigational Site

Kiel, Germany

GSK Investigational Site

Leipzig, Germany

GSK Investigational Site

Mainz, Germany

GSK Investigational Site

Athens, Greece

GSK Investigational Site

Athens, Greece

GSK Investigational Site

Athens, Greece

GSK Investigational Site

Bergamo, Italy

GSK Investigational Site

Bologna, Italy

GSK Investigational Site

Messina, Italy

GSK Investigational Site

Milan, Italy

GSK Investigational Site

Milan, Italy

GSK Investigational Site

Milan, Italy

GSK Investigational Site

Padova, Italy

GSK Investigational Site

Roma, Italy

GSK Investigational Site

Roma, Italy

GSK Investigational Site

Chiba, Japan

GSK Investigational Site

Ehime, Japan

GSK Investigational Site

Gunma, Japan

GSK Investigational Site

Hokkaido, Japan

GSK Investigational Site

Kagawa, Japan

GSK Investigational Site

Kagawa, Japan

GSK Investigational Site

Nara, Japan

GSK Investigational Site

Niigata, Japan

GSK Investigational Site

Osaka, Japan

GSK Investigational Site

Osaka, Japan

GSK Investigational Site

Osaka, Japan

GSK Investigational Site

Saitama, Japan

GSK Investigational Site

Shizuoka, Japan

GSK Investigational Site

Tokyo, Japan

GSK Investigational Site

DF, Mexico

GSK Investigational Site

Mexico City, Mexico

GSK Investigational Site

Monterrey, Mexico

GSK Investigational Site

Katowice, Poland

GSK Investigational Site

Mysłowice, Poland

GSK Investigational Site

Warsaw, Poland

GSK Investigational Site

Johannesburg, South Africa

GSK Investigational Site

Ansan, South Korea

GSK Investigational Site

Bucheon-si, South Korea

GSK Investigational Site

Daegu, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Seoul, South Korea

GSK Investigational Site

Suwon Gyeonggi-do, South Korea

GSK Investigational Site

Barcelona, Spain

GSK Investigational Site

Barcelona, Spain

GSK Investigational Site

Barcelona, Spain

GSK Investigational Site

León, Spain

GSK Investigational Site

Madrid, Spain

GSK Investigational Site

Madrid, Spain

GSK Investigational Site

Madrid, Spain

GSK Investigational Site

Santander, Spain

GSK Investigational Site

Seville, Spain

GSK Investigational Site

Valencia, Spain

GSK Investigational Site

Valladolid, Spain

GSK Investigational Site

Vigo, Spain

GSK Investigational Site

Stockholm, Sweden

GSK Investigational Site

Uppsala, Sweden

GSK Investigational Site

Kocaeli, İzmit, Turkey (Türkiye)

GSK Investigational Site

Diyarbakır, Sur, Turkey (Türkiye)

GSK Investigational Site

Adana, Yüreğir, Turkey (Türkiye)

GSK Investigational Site

Istanbul, Turkey (Türkiye)

GSK Investigational Site

Bristol, United Kingdom

GSK Investigational Site

Cambridge, United Kingdom

GSK Investigational Site

Glasgow Strathclyde, United Kingdom

GSK Investigational Site

Leeds West Yorkshire, United Kingdom

GSK Investigational Site

Liverpool, United Kingdom

GSK Investigational Site

London, United Kingdom

GSK Investigational Site

London, United Kingdom

GSK Investigational Site

Middlesbrough, United Kingdom

GSK Investigational Site

Plymouth, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06613698

Related Trials

Alcohol Misuse Treatment to Patients Newly Diagnosed With Alcohol-related Liver Disease: a Randomized Controlled Trial

NCT064937731 location

Screening At-risk Populations for Hepatic Fibrosis With Non-invasive Markers

NCT033089161 location